As the market for protein biotherapeutics expands, pressure increases to improve the efficiency and efficacy of the development process
At the recent American Society for Mass Spectrometry Conference (ASMS) in Philadelphia, Agilent Technologies announced the launch of the 6560C Ion Mobility LC/Q-TOF, as well as enhancements to the VWorks automation software suite and AssayMAP large capacity cartridges. The products are designed to improve the analysis of proteins and peptides to speed up the development of protein-based therapeutics in biopharma.
As the market for protein biotherapeutics expands, pressure increases to improve the efficiency and efficacy of the development process. The recently introduced products address specific stages of the development workflow, from sample preparation to secure protocols, and software to complex protein structural analysis.
“By expanding our instrument portfolio, software solutions, and sample preparation capabilities, Agilent delivers significant value for the development of biotherapeutics in this fast-growing market, allowing for deeper characterisation of proteins,” said Sudharshana Seshadri, VP and General Manager of Agilent’s Mass Spectrometry Division. “These introductions reinforce Agilent’s commitment to supporting and enhancing the speed of discovery and development of novel protein biotherapeutics to improve the quality of life.”
Brandon Ruotolo, Professor of Chemistry at University of Michigan, said: “The CIU technology has been transformative for my research. It has greatly enhanced our ability to develop rapid, structurally sensitive assays targeting systems ranging from large protein assemblies to biotherapeutic antibodies. I can’t wait to see what the future holds.”
The 6560C Ion Mobility Q-TOF adds capabilities designed to enhance flexibility and performance in comparison to its predecessors for precise measurements of large protein complexes such as biotherapeutic antibodies. Protein folding and structural analysis are now possible by CIU, the company says, while HRdm 2.0 postprocessing generates IM resolution of up to 250.
Features of the VWorks 14.1 automation software suite enhance support for 21 CFR Part 11 and Annex 11 with e-signatures and secure protocols for AssayMAP. VWorks 14.1 enables the adoption of automation and the Bravo platform in regulated environments.
The company has expanded the AssayMAP platform's portfolio of available chemistries with the introduction of Protein A affinity purification cartridges and reversed phase cartridges for antibody enrichment and peptide cleanup, respectively.